EXHIBIT 99.1
![]() | ![]() | |
Roche Diagnostics VP joins AION Board
Global nanotechnology company pSivida Limited(ASX:PSD, NASDAQ:PSDV, Xetra:PSI)ispleased to announce that its wholly owned subsidiary AION Diagnostics Limited, hasappointed Dr. Jörg Schreiber PhD as a Non-executive Director.
AION Diagnostics Managing Director Dr Anna Kluczewska said ‘We are proud to have adiagnostics industry leader with a proven track record in delivering results, join the AIONBoard. Dr. Schreiber brings with him leadership and expertise in commercialisation of worldclass diagnostic products.
Dr. Schreiber has over 20 years experience in the diagnostics industry whilst working with aglobal leader in the sector. Dr. Schreiber joined Roche Diagnostics in 1986 following themerger of Boehringer Mannheim in Germany, and during this time held key senior rolesincluding Vice President for R&D and Special Projects in the US, until his recent retirement. Under Dr. Schreiber’s leadership, Accu-Chek Advantage, the world’s leading diabetesmonitoring system was launched, and grew into its current position of significance for RocheDiagnostics. As the Vice President of R & D based in the US, Dr. Schreiber has broadexperience in diagnostic product development.
Dr Schreiber said he was very impressed with the opportunities for BioSilicon™ in diagnosticsand sees the company commercialising innovative solutions for key markets. Dr. Schreiber has been elected to be the incoming Chairman of the State of Indiana HealthIndustry Forum, an important policy setting & economic development organisation for a keydiagnostics industry cluster in the US. Dr. Schreiber holds a Ph.D in Physics from GiessenUniversity where he specialised in biophysics.
pSivida has funded AION’s first year of operations and has licensed diagnostic applications ofBioSilicon™ to AION.
-ENDS-
Releasedby: | |
In Australia: | In US: |
Josh Mann, CFA | Beverly Jedynak |
Investor Relations | President |
pSivida Limited | Martin E. Janis & Company, Inc. |
Tel: + 61 8 9226 5099 | Tel: 312-943-1100 ext. 12 |
joshuamann@psivida.com | bjedynak@janispr.com |
NOTES TO EDITORS:
pSivida Limited
pSivida is a global nanotechnology company committed to the biomedical sector and the development ofproducts in healthcare. The company’s focus is the development and commercialisation of a modifiedform of silicon (porosified or nano-structured silicon) known as BioSilicon™. As a new and excitingbiocompatible material, BioSilicon™ offers multiple potential applications across the high growthhealthcare sector, including controlled release drug delivery, targeted cancer therapies (includingbrachytherapy and localized chemotherapy), tissue engineering and orthopedics. Potential diagnosticsapplications are being developed through its subsidiary AION Diagnostics Limited.
pSivida owns the intellectual property rights to BioSilicon™ for use in or on humans and animals. The IPportfolio consists of 26 patent families, 29 granted patents and over 80 patent applications. The corepatent, which recognises BioSilicon™ as a biomaterial was granted in the UK in 2000 and in the US in2001.
pSivida is listed on NASDAQ (PSDV), the Australian Stock Exchange (PSD) and in Germany on theFrankfurt Stock Exchange on the XETRA system (German Symbol: PSI. Securities Code (WKN)358705). pSivida’s shares also trade in the United Kingdom on the OFEX International Market Service(IMS) under the ticker symbolPSD.
The Company’s strategic partner and largest shareholder is the QinetiQ group, the largest science andtechnology company in Europe. QinetiQ is the former UK government Defence Evaluation ResearchAgency and was instrumental in discovering BioSilicon™. pSivida enjoys a strong relationship withQinetiQ having access to its cutting edge research and development facilities. For more information onQinetiQ visitwww.qinetiq.com.
For more information visitwww.psivida.com
This document contains forward-looking statements that involve risks and uncertainties. Although we believe that the expectations reflectedin such forward-looking statements are reasonable at this time, we can give no assurance that such expectations will prove to be correct. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Actual results coulddiffer materially from those anticipated in these forward-looking statements due to many important factors including: our failure to developapplications for BioSiliconTMdue to regulatory, scientific or other issues. Other reasons are contained in cautionary statements in theRegistration Statement on Form 20-F filed with the U.S. Securities and Exchange Commission, including, without limitation, under Item 3.D,"Risk Factors" therein. We do not undertake to update any oral or written forward-looking statements that may be made by or on behalf ofpSivida.